U.S. FDA Plans Permanent Offices In China In Wake Of Heparin Scare
This article was originally published in PharmAsia News
Executive Summary
In the wake of a safety scare over Chinese-imported heparin API, U.S. FDA announced March 14 that it will establish permanent offices in Beijing, Guangzhou and Shanghai, staffed by eight full-time employees and five local Chinese nationals
You may also be interested in...
Focused On Globalization, Shanghai FDA Will Hold International Forum On Drug Safety And Regulatory Change
BEIJING - In an effort to fast-forward the globalization of China's drug laws and utlimately boost its exports of pharmaceuticals, the Shanghai FDA is partnering with a U.S.-based law firm to co-host its first international forum on drug safety and regulatory change
Focused On Globalization, Shanghai FDA Will Hold International Forum On Drug Safety And Regulatory Change
BEIJING - In an effort to fast-forward the globalization of China's drug laws and utlimately boost its exports of pharmaceuticals, the Shanghai FDA is partnering with a U.S.-based law firm to co-host its first international forum on drug safety and regulatory change
Shanghai FDA Signs Agreement With U.S. Law Firm To Foster International Cooperation on Drug Regulation
BEIJING - A new government think tank focused on health-sector regulatory reform and international cooperation set up by the Shanghai FDA will work closely with a U.S.-based law firm to review drug laws worldwide and to host a series of global exchanges